However, the functionally weaker inhibitory <i>KIR2DL1*004</i>+<i>C2</i> interaction conferred ALL risk (<i>p</i> = 0.01) in individuals with the <i>KIR Bx</i> genotype. The gene discussed is KIR3DL1; the disease is acute lymphoblastic leukemia.